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Abstract: 
Aim: In this study, we explored the angiogenic potential and proangiogenic concentration ranges of 2-
deoxy-D-ribose (2dDR) and  ? ?ɴ-Estradiol (E2) in comparison with vascular endothelial growth factor 
(VEGF). 2dDR and E2 were then loaded into tissue engineering (TE) scaffolds to investigate their 
proangiogenic potential when released from fibres. Materials and Methods: Ex-ovo chick chorioallantoic 
membrane (CAM) assay was used to evaluate angiogenic activity of 2dDR and E2. Both factors were then 
introduced into scaffolds via electrospinning to assess their angiogenic potential when released from 
fibres. Results: Both factors were approximately 80% as potent as (VEGF) and showed a dose-dependent 
angiogenic response. The sustained release of both agents from the scaffolds stimulated 
neovascularisation over 7 days in the CAM assay. Conclusion: We conclude that both 2dDR and E2 provide 
attractive alternatives to VEGF for the functionalisation of TE scaffolds to promote angiogenesis in vivo. 
Graphical abstract:  
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1. INTRODUCTION 
Over the last 30 years there have been significant advances in the production of tissue engineered 
materials suitable for use in the clinic. However, one of the key challenges is to ensure rapid 
neovascularisation into these constructs in order for them to survive post transplantation [1]. While 
relatively thin simple tissue engineered constructs can survive on well-vascularised wound beds, thicker 
constructs (>200 µm) usually fail to engraft due to lack of oxygen and nutrients in vivo [2,3]. Both 
prevascularisation and scaffold functionalisation strategies with the use of angiogenic factors are viewed 
as promising approaches to accelerate vascular ingrowth into tissue engineering (TE) constructs to 
circumvent slow vascularisation after implantation [1,4].  
Although there are some well-known growth factors such as transforming growth factor-beta (TGF-ɴ ? ?
platelet derived growth factor (PDGF) and fibroblast growth factor (FGF) which have the potential to 
promote neovascularisation [5], vascular endothelial growth factor (VEGF) is recognised to be the most 
well-studied angiogenic factor due to occupying a key role in the angiogenic cascade. VEGF has been 
proven to have important roles in different steps of the angiogenic process in vivo: vasodilation and 
permeability, destabilization of vessels and degradation of extracellular matrix (ECM), proliferation and 
migration of endothelial cells, and lumen formation and vessel stabilisation [6,7].  
VEGF acts as part of a well-regulated process, and its actions are highly dose-dependent. It is largely bound 
to glycosaminoglycans in vivo and released in response to need. Its angiogenic potential has been assessed 
in many in vitro studies such as cell migration assays using matrigel [8], collagen gels [9] and transwell 
migration assays [10]. It has also been evaluated in the CAM assay [11 W14] as well as in vivo studies. 
However, a range of studies show that VEGF addition can lead to excessively leaky [15], permeable [16] 
and haemorrhagic [17] vessels such as those that are found in tumorigenesis [18]. Controlled and slow 
release of VEGF may help to regulate the delivery rate of VEGF and circumvent these problems by creating 
mature, more durable and stable vessels [19,20]. One promising approach is to use the glycosaminoglycan 
heparin, which is found on the cell surface and in ECM [21], to bind VEGF. Heparin found in ECM plays a 
role in storage and prolonging the release of heparin binding growth factors such as FGF and VEGF. It also 
regulates their stability and biological activity as well as long-term stimulation of endothelial cells [22 W24]. 
Our group has explored the approach of using heparin bound to biomaterials to deliver VEGF using a layer-
by-layer method for coating scaffolds with heparin and then binding VEGF [25] and we have also reported 
on chitosan-based hydrogels for binding heparin [26,27]. However, binding VEGF with heparin is a long 
process and requires multistep actions to introduce VEGF with the TE scaffolds.  
As an alternative to VEGF,  ? ?ɴ-Estradiol (E2) has been shown to promote endothelial cell migration and 
proliferation in vitro [28,29] and to stimulate new blood vessel formation both in vitro and in vivo [30]. E2 
has an important role in neovascularisation during the menstrual cycle [31,32]. It is used clinically in the 
treatment of osteoporosis and heart disease [33]. Moreover, blocking the E2 receptor with adjuvants such 
as tamoxifen for estrogen receptor positive tumours, in which high estrogen helps the cancer cells grow 
and spread, is an effective method to reduce tumour vasculature. This therapy has been in clinics for many 
years especially for treatment of breast cancer [34,35]. Recently, our group confirmed that poly-L-lactic-
acid (PLLA) scaffolds loaded with E2 were highly angiogenic using the CAM assay [36]. 
  
 
Thymidine phosphorylase (dThdPase) has an amino acid sequence identical to platelet-derived 
endothelial cell growth factor (PD-ECGF) and is an enzyme that catalysis the conversion of thymidine to 
thymine [37,38]. Activation of dThdPase is known to be angiogenic [39 W41] although its molecular 
mechanism is still unclear. 2-deoxy-D-ribose (2dDR), one of the degradation products of thymidine, was 
reported to have a chemotactic activity and angiogenic activity in vivo [42,43]. However, no other similar 
molecules including thymidine, thymine, 2-deoxy-L-ribose, 2-deoxy-D-ribose-1-phosphate were found to 
be angiogenic when compared to 2dDR [43,44]. Similarly, our group previously found that 2dDR, released 
from a hydrogel, is not only angiogenic but also stimulates wound healing in a rat skin wound model [45]. 
However, as only a single dose of 2dDR was used in that study, dose-dependent response to 2dDR 
remained still unclear. 
In summary, although VEGF is a highly effective stimulator of angiogenesis, it has also been demonstrated 
to be unstable, expensive and possibly unsafe when given in a non-regulated manner. Thus, there is need 
to explore alternative strategies for positively influencing the angiogenic cascade due to the potential 
drawbacks of using exogenous VEGF. E2 has proven as safe to be used clinically. To date, the angiogenic 
response to different doses of E2 has been studied by several groups [46 W48]. On the other hand, although 
potential angiogenic effect of 2dDR has been previously reported, there have not been any studies so far 
on the concentration range of 2dDR which is proangiogenic.  
Accordingly, our aim in this study is to establish useful proangiogenic concentration ranges for both 2dDR 
and E2 and to compare their angiogenic activities with VEGF to progress our understanding of the 
potential value of E2 and 2dDR to the world of proangiogenic biomaterials and to the problem of 
improving rapid neovascularisation in tissue engineered constructs. In order to satisfy this aim, we 
explored the angiogenic potential of different concentrations of 2dDR and E2 in order to determine the 
effective dose ranges of both agents which were found approximately 80% as potent as VEGF for 
promoting angiogenesis when applied directly on CAM. Following the determination of the effective doses 
of the 2dDR and E2, both drugs were loaded into a simple electrospun scaffold of Poly3-hydroxybutyrate-
co-3-hydroxyvalerate (PHBV) fibres from which they were readily released. PHBV was selected due to its 
biodegradability and good biocompatibility which can be linked with its degradation product is 3-
hydroxybutyrate that is also a natural product produced in human body [49]. The release of both agents 
from fibres also showed an increased angiogenic activity in CAM assay and stimulated neovascularisation 
in vivo.  
Therefore, for the first time in this study, we defined effective pro-angiogenic concentration ranges of 
2dDR and compared it with E2 and VEGF in CAM assay in which one can demonstrate significant increases 
in blood vessel formation within seven days, which is a time period very relevant to driving angiogenesis 
non-healing chronic wounds in vivo and to stimulating the formation of new blood vessels after 
engraftment of TE constructs. 
 
 
 
  
 
2. MATERIALS AND METHODS 
2.1. Ex-ovo CAM assay 
2.1.1. Incubation of eggs 
All CAM experiments were carried out according to the Home Office, UK guidelines. Schematic 
demonstration of the ex-ovo CAM assay is given in Figure 1. Fertilised chicken eggs (Gallus domesticus) 
were purchased from Henry Stewart & Co. (MedEggs, Norwich, UK). The eggs were carefully wiped with 
20% industrial methylated spirit solution using hand paper towels to remove dirt and feathers from the 
shell.  The eggs were then incubated at 37.5 °C until embryonic development day (EDD) 3, lying 
horizontally in a humidified egg incubator (RCOM King SURO, P&T Poultry, Powys, Wales). 
2.1.2. Transferring the embryos into petri dishes 
On EDD 3, the upper surface of the eggs was marked with a felt pen. The eggs were held horizontally (with 
the marked surface on top) and cracked on the edge of a 1000 ml glass beaker and kept close to the 
bottom surface of the petri dishes. The embryos were then transferred gently into sterile petri dishes and 
kept in a humidified incubator (Binder, Tuttlingen, Germany) at 38°C. 
 
Figure 1. Schematic illustration of the steps of the direct application of the substances and implantation 
of the substance releasing scaffolds on CAM. This figure shows the basic methodology of ex-ovo CAM 
assay and quantification of the macro and micro images. 
2.2. Determination of the optimum concentration of E2 and 2dDR on angiogenesis using the CAM 
assay 
2.2.1. Preparation of drug solutions 
Three concentrations of E2 and 2dDR were screened in these experiments. E2 was dissolved in methanol 
then working solutions were prepared with phosphate buffered saline (PBS) so as to be (a) 100 ng/day 
(E2-100), (b) 200 ng/day (E2-200), and (b) 600 ng/day (E2-600) concentrations. 2dDR solutions were 
prepared by dissolving in PBS so as the final concentrations to be (a) 20 µg/day (2dDR-20), (b) 200 µg/day 
(2dDR-200), and (c) 1000 µg/day (2dDR-1000). VEGF was used as a positive control at a concentration of 
80 ng/day (VEGF-80) whereas Sunitinib, an inhibitor of multiple receptor tyrosine kinases, was used as a 
  
 
negative control at a 2 µg/day concentration. Working solutions of all substances were prepared freshly 
at the beginning of each experiment. All chemicals were purchased from Sigma Aldrich unless indicated 
otherwise. 
2.2.2. Application of drugs onto the CAM 
Plastic rings (~6.5 mm in diameter), as a reservoir for the drugs and a marker for the implantation area, 
were placed on the CAM. The substances were applied as 20 µl volume onto the CAM twice a day for 3 
days starting from EDD 7. On EDD 11, images of the CAM area circumscribed by the plastic rings were 
acquired using a digital microscope and embryos were sacrificed immediately after image acquisition. 
2.2.3.  Quantification of angiogenesis 
Digital images were used for quantification of the results. Multiple image processing steps were applied 
following previously described protocols [6,7,50]. Firstly, the internal area of the ring was cropped, and 
the raw image was split to its three main colour channels (red, green and blue (RGB) channels) using 
Adobe Photoshop CS6 (ADOBE Systems Inc., San Jose, California, USA). Only the green channel was 
exported as an image file and then imported to ImageJ (Wayne Rasband, National Institutes of Health, 
USA) for further analysis including unsharp mask filtering, enhancing the local contrast, noise removal, 
converting the image to binary and segmentation. The green channel was selected because it gave the 
most accurate and detailed results for blood vessels when converted to binary [51]. Finally, the number 
of branch points was quantified using quantification software (AngioTool, National Cancer Institute, USA) 
and average blood vessel lengths were calculated by using binary image histograms with known pixel/mm 
ratios in ImageJ (Wayne Rasband, National Institutes of Health, USA). 
2.3. Evaluation of effect of E2 and 2dDR on microvasculature 
For these experiments only, one concentration of E2 (E2-200) and 2dDR (2dDR-200) were used as these 
concentrations were the most effective ones in terms of stimulating angiogenesis in CAM assay. The drugs 
were applied following the steps in section 2.2.2. 
2.3.1. Microinjection 
At EDD 11, a 20% solution of rhodamine labelled lens culinaris agglutinin (LCA) (Vector Laboratories, 
Peterborough, UK) was injected into the circulation of CAM using 30 G needles under a dissection 
microscope (Wild Heerbrugg, Heerbrugg, Switzerland) to visualize the microvasculature. After 1 min of 
incubation, embryos were sacrificed and areas on CAM circumscribed by the plastic ring were removed 
and fixed in 3.7% formaldehyde solution. Fixed CAM samples were then imaged under a confocal 
microscope (Zeiss LSM 510 Meta, Jena, Germany) for investigating the effect of substances on the 
microvascular structure of the CAMs. 
2.3.2. Quantification of the vascular area  
The percentage vascular areas (VA%) of the microvasculature of CAMs were quantified using confocal 
images of LCA injected CAM samples as shown in Figure 3. The images were then imported to ImageJ and 
  
 
converted to binary images after filtering and smoothing processes prior to quantification. VA% was 
calculated using the histogram list of black and white areas in the image. 
2.4. Construction of E2 and 2dDR releasing PHBV scaffolds  
2.4.1. Electrospinning E2 and 2dDR loaded PHBV scaffolds 
Preparation of the solutions 
10% (w/w) PHBV solution was prepared prior to electrospinning. 1 g of PHBV granules (Goodfellow, 
London, UK) were dissolved in 1 g of methanol (Fisher Scientific, Massachusetts, USA) and 8 g of DCM 
(Fisher Scientific, Massachusetts, USA) in a fume hood. Four 10% PHBV solutions were prepared prior to 
addition of the drugs. Finally, 25 mg E2, 50 mg of E2, 250 mg of 2dDR and 500 mg of 2dDR were then 
added to each solution per 1 g of PHBV. The solutions were mixed using magnetic stirrer overnight. 
Electrospinning 
Solutions (~10 ml) were loaded into 10 ml syringes fitted with 0.6 mm inner diameter syringe tips. Syringes 
were then placed in a syringe pump (GenieTMPlus, KentScientific, Connecticut, USA). Aluminium foil was 
used as the collector and placed at a distance of 17 cm from the needle tips. The pump was set to 40 
µl/min, and 17 kV voltage was applied both to the collector and the tips. Electrospinning was done at 
room temperature until all the polymer solution was used. 
2.4.2. Characterization of the scaffolds 
Scanning electron microscopy (SEM) 
The surface morphology of E2 and 2dDR releasing scaffolds were observed under SEM (Philips/FEI XL-20 
SEM; Cambridge, UK). The samples were coated with gold using a gold sputter (Edwards sputter coater 
S150B, Crawley, England) prior to imaging. Fiber diameter and pore sizes were measured using ImageJ. 
E2 and 2dDR release from the scaffolds 
Scaffolds were cut into pieces so to fit into a 6-well plate, weighed and submerged in 4 ml of PBS. The 
accumulative E2 and 2dDR concentrations released from each group (25 mg E2, 50 mg E2, 250 mg 2dDR, 
500 mg 2dDR) were measured fluorometrically using a UV-VIS spectrophotometer (Thermo Fischer 
Evolution 220, Massachusetts, USA) at 238 nm for 2dDR and 220 nm for E2. Absorbance values were 
converted into concentrations using a standard curve of known concentrations of E2 and 2dDR. 
Effect of the drugs on mechanical properties of the scaffolds 
Biomechanical testing samples were prepared by cutting 20 mm x 10 mm pieces from dry scaffolds. The 
clamps of the device were positioned 10 mm away from each other, and the width and thickness of each 
scaffold were measured. Test samples were clamped with two grips in a tensiometer (BOSE Electroforce 
Test Instruments, Minnesota, USA). Tensile tests were performed on each sample at a rate of 0.1 mm/s 
until the samples failed (n=4). The raw data of these tests were used for drawing stress-strain and load-
  
 
ĚŝƐƉůĂĐĞŵĞŶƚŐƌĂƉŚƐ ?hůƚŝŵĂƚĞƚĞŶƐŝůĞƐƚƌĞŶŐƚŚ ?hd^ ?ǁĂƐĐĂůĐƵůĂƚĞĚĨƌŽŵƐƚƌĞƐƐ ?ʍ ?ĂŶĚƐƚƌĞƐƐ ?ɸ ?ĐƵƌǀĞƐ
ŽĨĞĂĐŚƐĂŵƉůĞ ?ǁŚŝůĞƐƚŝĨĨŶĞƐƐǁĂƐĐĂůĐƵůĂƚĞĚĨƌŽŵůŽĂĚ ?& ?ĂŶĚĚŝƐƉůĂĐĞŵĞŶƚ ?ȴ> ?ĚĂƚĂ ? 
Wettability tests of drug releasing electrospun scaffolds were also undertaken using a drop shape analyser 
(Krüss DSA100, Germany) under ambient laboratory conditions in order to see the effect of E2 and 2dDR 
on wettability of the scaffolds. In brief, a 5 µl water droplet was dropped onto the scaffold surface, and 
the retention times of the droplet on scaffolds before complete absorption were calculated from recorded 
movies of the tests. At least nine measurements (three drops on three different substrates) were taken 
for measuring the water retention time on each sample. 
2.5. Evaluation of angiogenic potential of the E2 and 2dDR releasing electrospun PHBV scaffolds 
2.5.1. Implantation of the E2 and 2dDR releasing scaffolds on CAM 
Scaffolds were cut into 5.5 mm diameter circles using a laser cutting machine (Epilog Laser Cutter, 
Clevedon, UK) and sterilised under UV light for 1 hour prior to implantation. Two circular scaffolds were 
placed on CAM at EDD 7 and embryos were cultured for further 7 days.  
2.5.2. Quantification of the angiogenic activity of the drug releasing scaffolds 
Images of the scaffolds implanted on CAM were acquired using a digital microscope at EDD 14. Embryos 
were then sacrificed and scaffolds were cut together with a rim of surrounding CAM tissue and fixed in 
3.7% formaldehyde solution. Angiogenesis was quantified by counting all blood vessels growing towards 
the scaffolds in a spoke wheel pattern, as described previously [36]. 
2.5.3. Histological evaluation of the E2 and 2dDR releasing scaffolds on CAM 
Haematoxylin and Eosin (H&E) staining was performed on cell impregnated scaffolds by modifying a 
standard protocol [52]. Briefly, fixed samples were embedded in optimal cutting temperature freezing 
medium and frozen in liquid nitrogen for 3 minutes. Sections were cut 8-10 µm thick using a cryostat (Leica 
Biosystems Nussloch, Germany) at -20°C. Sections were then stained with haematoxylin for 90 seconds 
and eosin for 5 minutes. Finally, H&E images were acquired under a light microscope (Motic DM-B1, 
Xiamen, China). The total number of blood vessels adjacent to the scaffolds were quantified by counting 
blood vessels in H&E sections [53]. Briefly, all discernible blood vessels adjacent to the scaffolds were 
counted by two independent researchers using two independent microscopes at 10× magnification. Three 
independent CAM experiments were conducted, and in each independent experiment, six embryos were 
used for each group. For histological analysis of a single group, three embryos were randomly selected 
out of six embryos from each independent experiment. Six sections were taken on a slide from each of 
the nine samples, and each slide was investigated under a microscope making a total of 54 counts per 
group for quantification of the results. 
 
 
  
 
2.6. Statistics 
^ƚĂƚŝƐƚŝĐĂůĂŶĂůǇƐĞƐǁĞƌĞƉĞƌĨŽƌŵĞĚƵƐŝŶŐƵŶƉĂŝƌĞĚƐƚƵĚĞŶƚ ?Ɛƚ-test. P values <0.05 were considered as 
ƐƚĂƚŝƐƚŝĐĂůůǇƐŝŐŶŝĨŝĐĂŶƚ ?ĂŶĚƚŚĞĚĞŐƌĞĞŽĨƐŝŐŶŝĨŝĐĂŶĐĞǁĂƐŝŶĚŝĐĂƚĞĚǁŝƚŚŶƵŵďĞƌŽĨƐƚĂƌƐ ? ? ? ? ?WA? ? ? ?001, 
 ? ? ?WA? ? ? ? ? ? ? ? ?WA? ? ? ? ? ? ?WA? ? ? ? ? ?ns PA? ?  ? ? ?
3. RESULTS 
3.1. Assessment of angiogenic activity of E2 and 2dDR on CAM 
Quantification of the macroimages of CAMs showed that E2-100, E2-200 and E2-600 groups increased the 
number of branch points 1.3-fold, 1.5-fold and 1.4-fold respectively. All concentrations increased the 
average vessel length approximately 1.2-fold compared to controls over 4 days. In the same way, 2dDR-
20 and 2dDR-200 increased the number of branch points by 1.3 times and 1.4 times, respectively. Both 
concentrations increased the average vessel length approximately 1.2 times while there was no significant 
difference for the 2dDR-1000 group compared to control scaffolds. VEGF increased the number of branch 
points by 1.4-fold and the average vessel length by 1.7-fold. Quantification of the branch points, average 
vessel lengths and the macroimages of the CAMs with the most effective concentrations of E2 (E2-200) 
and 2dDR (2dDR-200) are shown in Figure 2. 
 
Figure 2. Evaluation of different concentrations of E2 and 2dDR to stimulate new blood formation in a 
chorioallantoic membrane assay. Three concentrations of both drugs were compared against a negative 
  
 
(Sunitinib), PBS and positive (VEGF) control in these experiments. A normal angiogenic response can be 
seen in the PBS group. A significant increase in the average length of blood vessels and number of branch 
points compared with PBS can be observed for both E2 and 2dDR groups (upper row). Representative 
images are given for E2 (200 ng/day) and 2dDR  ? ? ? ?ʅŐ ?ĚĂǇ ? ?WƌŽĐĞƐƐĞĚŝŵĂŐĞƐƵƐĞĚĨŽƌƋƵĂŶƚŝĨŝĐĂƚŝŽŶŽĨ
results are given for each group (middle row). ****p A? ? ? ? ? ? ? ? ? ? ?ƉA? ? ? ? ? ? ? ? ?ƉA? ? ? ? ? ? ?ƉA? ? ? ? ? ?ŶƐƉA?
0.05, n = 9 ± standard deviation. The number of branch points and average macrovessel lengths seen in 
response to different concentrations of E2 and 2dDR were calculated and compared with PBS controls 
over 4 days (lower row). Values represent mean ± standard deviation. Scale bars represent 1 mm.  
2dDR: 2-Deoxy-ƌŝďŽƐĞ ? ? P ? ?ɴ-Estradiol; ns: Non significant; PBS: Phosphate-buffered saline 
3.2. Effect of E2 and 2dDR on the microstructure of CAM 
Microvascular evaluation of the CAM samples showed that VA% was increased from 55.3 ± 3% to 79.5 ± 
5% and 71.7 ± 3% for E2 and 2dDR applied groups respectively compared to controls over 4 days. VEGF 
and Sunitinib were used as positive and negative controls. Although the VA% was significantly higher in 
VEGF groups when compared with 2dDR and E2 applied CAMs, VEGF also resulted in smaller lacunae 
formation. Sunitinib, as an inhibitor of angiogenesis, led to much larger lacunae (Figure 3). 
 
Figure 3. Demonstration of the effect of Estradiol (E2) and 2-deoxy-D-ribose (2dDR) on microvasculature 
compared with the application of phosphate-buffered saline (control). Rhodamine-labelled LCA was 
injected into the circulation of the chorioallantoic membrane to visualize microvasculature. The vascular 
areas were labelled with red colour which indicates LCA-positive areas (A). Similar to VEGF group, an 
endothelial cell hypertrophy together with smaller lacunae compared with PBS can be observed for both 
E2 and 2dDR groups (B). Percentage area covered by endothelial cells (microvasculature) were calculated 
for each group and compared (C). The 2dDR was ĂƉƉůŝĞĚĂƐ ? ? ?ʅŐ ?ĚĂǇĂŶĚ ?ĂƐ ? ? ?ŶŐ ?ĚĂǇ ? ? ? ? ?ƉA?
 ? ? ? ? ? ? ? ? ? ?ƉA? ? ? ? ? ?ĐŽŵƉĂƌĞĚǁŝƚŚW^ ?ŶA? ?A?ƐƚĂŶĚĂƌĚĚĞǀŝĂƚŝŽŶ ?^ĐĂůĞďĂƌƐƌĞƉƌĞƐĞŶƚ ? ?ʅŵ ? 
2dDR: 2-Deoxy-ƌŝďŽƐĞ ? ? P ? ?ɴ-Estradiol; LCA: Lens culinaris agglutinin; PBS: Phosphate-buffer saline. 
  
 
3.3. Characterization of the E2 and 2dDR releasing PHBV scaffolds 
3.3.1. Effect of including E2 and 2dDR on the ultrastructure of the PHBV scaffolds 
SEM images of the E2 and 2dDR releasing PHBV scaffolds can be seen in Figure 4. The diameters of the 
fibres were significantly increased by addition of substances in all groups (25 mg E2 (0.83 ± 0.17 µm), 50 
mg E2 (0.98 ± 0.35 µm), 250 mg 2dDR (0.89 ± 0.19 µm), 500 mg 2dDR (1.22 ± 0.28 µm)) added PHBV 
scaffolds when compared with the PHBV control group (0.66 ± 0.16 µm) as shown in the graph on the 
bottom right corner of Figure 4. 
 
Figure 4. Scanning electron microscopy images of the scaffolds. (A) Plain PHBV, (B) PHBV + 25 mg E2, (C) 
PHBV + 50 mg E2, (D) PHBV + 250 mg 2dDR, (E) PHBV + 500 mg 2dDR. The graph on the bottom left corner 
shows the distribution of fiber diameters for each ƐĐĂĨĨŽůĚ ?  ? ? ? ?Ɖ A?  ? ? ? ? ? ? ?  ? ? ?Ɖ A?  ? ? ? ? ? ? ^ĐĂůĞ ďĂƌƐ
ƌĞƉƌĞƐĞŶƚ ? ? ?ʅŵ ? 
2dDR: 2-Deoxy-ƌŝďŽƐĞ ? ? P ? ?ɴ-Estradiol; PHBV: Poly3-hydroxybutyrate-co-3-hydroxyvalerate. 
3.3.2. Release of E2 and 2dDR from PHBV scaffolds over 30 days 
The rate of release of E2 and 2dDR from scaffolds was assessed over 30 days as shown in Figure 5A. By 7 
days, 2dDR release from the scaffolds was 81.3% and 86.5% of the total 2dDR present in the polymer 
solution for 250 mg and 500 mg 2dDR scaffolds, respectively. In contrast the total E2 release from scaffolds 
within 7 days represented 1.3% and 1.6% of the initial E2 present in the polymer solution for 25 mg and 
50 mg E2 scaffolds, respectively. 
3.3.3. Comparison of the effects of E2 and 2dDR on the mechanical properties of scaffolds 
When each scaffold was produced using the same volume of polymers, the thicknesses of the scaffolds 
were measured 105 ± 22 µm, 84 ± 13 µm, 62 ± 10 µm, 136 ± 12 µm, and 124 ± 13 µm for plain, 25 mg E2, 
50 mg E2, 250 mg 2dDR, and 500 mg 2dDR added PHBV scaffolds, respectively. As can be seen from Figure 
  
 
5B, addition of all substances significantly increased the UTS of PHBV scaffolds when compared with plain 
PHBV scaffolds. Addition of E2 increased the UTS of the scaffolds more when compared with 2dDR added 
groups. Similarly, the stiffness of the scaffolds loaded with 2dDR and E2 was significantly higher compared 
to unloaded PHBV scaffolds. 250 mg 2dDR loading increased the stiffness of the PHBV scaffolds to the 
greatest extent as shown in Figure 5B. The wettability of the drug releasing scaffolds was investigated 
through a droplet retention time which is calculated using a drop shape analyser. Retention time of the 
water droplet on drug released scaffolds was calculated from recorded videos and given in Figure 5C. The 
water retention time on the 50 mg E2 loaded scaffolds increased to 198.3 ± 1.4 s from 16.7 ± 1.4 s 
observed for plain PHBV groups. In contrast, addition of 250mg 2dDR decreased the water retention time 
on scaffolds down to 2.3 ± 0.3 s. This showed that 2dDR loading made the scaffolds more wettable while 
the addition of E2 made the scaffolds less wettable. 
 
Figure 5. Assessment of the 2dDR and E2 release from the fibers over 30 days, and the effect of both 
drugs on mechanical properties of the scaffolds. (A) Release of 2dDR and E2 from PHBV scaffolds over 30 
days, n = 6 ± standard deviation. (B) Comparison of UTS and stiffness and (C) droplet retention time on 
ƚŚĞƐĐĂĨĨŽůĚƐ ? ? ? ? ?ƉA? ? ? ? ? ? ? ? ? ? ?Ɖ A? ? ? ? ? ? ? ? ?ƉA? ? ? ? ? ? ?ƉA? ? ? ? ? ?ŶA? ?A?ƐƚĂŶĚĂƌĚĚĞǀŝĂƚŝŽŶ ?  
2dDR: 2-Deoxy-ƌŝďŽƐĞ ? ? P ? ?ɴ-Estradiol; PHBV: Poly3-hydroxybutyrate-co-3-hydroxyvalerate; UTS: 
Ultimate tensile strength. 
3.4. Assessment of angiogenic potential of the E2 and 2dDR releasing scaffolds 
Assessment of E2 and 2dDR releasing scaffolds on CAM demonstrated that all groups at least doubled the 
number of discernible blood vessels growing towards the scaffolds in comparison with plain PHBV 
  
 
scaffolds as can be seen in Figure 6. Mean vessel counts for 25 mg E2 loaded scaffolds and 50 mg E2 loaded 
scaffolds were 49. ? ?A? ? ? ? ? ? ? ? ? ? ?WA? ? ? ? ? ? ? ?ĂŶĚ ? ? ? ? ?A? ? ? ? ? ? ? ? ? ? ?WA? ? ? ƌĞƐƉĞĐƚŝǀĞůǇ ?ǁŚŝůĞŝƚǁĂƐ
 ? ? ? ? ?A? ? ? ? ? ? ? ? ? ? ?WA? ? ? ? ? ? ? ?ĂŶĚ ? ? ? ? ?A? ? ? ? ? ? ? ? ? ? ?WA  ?  ? ? ? ? ?ĨŽƌ ? ? ?ŵŐĂŶĚ ? ? ?ŵŐ ?ĚZůŽĂĚĞĚ
scaffolds, respectively when compared with control groups (mean vessel count: 23.1 (±1.24)). None of the 
loaded substances affected the embryo survival rate which was over 75% for each group. 
 
Figure 6. Representative images demonstrating the angiogenic potential of 2-dDR (250 mg and 500 mg) 
and E2 (25 mg and 50 mg) releasing scaffolds in comparison with PHBV scaffolds. The graph on the bottom 
left shows the quantitative data from these experiments-ŵĞĂŶǀĞƐƐĞůĐŽƵŶƚƐ ? ? ? ? ?ƉA? ? ? ? ? ? ? ?^ĐĂůĞďĂƌƐ 
represent 3 mm, n = 6 ± standard deviation.  
2dDR: 2-Deoxy-ƌŝďŽƐĞ ? ? P ? ?ɴ-Estradiol; PHBV: Poly3-hydroxybutyrate-co-3-hydroxyvalerate. 
3.5. Histological analysis of the E2 and 2dDR releasing scaffolds on CAM 
All groups showed good biocompatibility and similar changes in the structure of CAM with a small increase 
in cell density in the mesoderm layer in all scaffold groups. The mean number of blood vessels adjacent 
to the scaffolds was significantly increased in response to all concentrations of both E2 and 2dDR releasing 
scaffolds when compared with controls and CAM only groups (see Figures 7 and 8). 
All scaffolds whether loaded with pro-angiogenic agents or unloaded showed good attachment to the 
CAM, and all membranes showed similar cellular infiltration. Figure 7 shows representative histology 
images.  
  
 
 
Figure 7. Histological analysis of chorioallantoic membranes after 7 days of incubation with or without 
scaffolds in different magnifications. Orientation of the scaffold(s), CAM ectoderm (*), mesoderm (**) and 
endoderm (***) layers were indicated in the images. Green arrows show the blood vessels. Scale bars = 
0.2 mm (10×), 0.1 mm (20×), 0.05 mm (40×).  
CAM: Chorioallantoic membrane; PHBV: Poly3-hydroxybutyrate-co-3-hydroxyvalerate. 
  
 
 
Figure 8. Quantification of the discernible blood vessels adjacent to the scaffolds at 10× magnification 
from the total of six different slides for each group and six different area of interest from each slide.  
CAM: Chorioallantoic membrane; ns: Non significant; PHBV: Poly3-hydroxybutyrate-co-3-
hydroxyvalerate. 
4.  DISCUSSION 
As laboratory production of tissue engineered materials has progressed to the clinic it has become clear 
that one of the critical barriers to their success is the need to achieve rapid (within 5 days) 
neovascularisation post implantation. Rapid ingrowth and infiltration of blood vessels are crucial for 
biomaterials to be able to survive in vivo [54]. The need for improved neovascularisation is crucial for 
tissue engineering, and our laboratory has been seeking to develop biomaterials to promote angiogenesis. 
As already stated, the approach which has been the most investigated is to deliver the major 
proangiogenic growth factor VEGF, or more recently to co-deliver it with the naturally occurring 
glycosaminoglycan heparin to which it would normally be bound in vivo. The MacNeil group and many 
others have sought to deliver materials which bind heparin and are therefore attractive to the binding of 
VEGF [25,26]. However, introducing VEGF with the TE scaffolds requires multistep actions and a long 
process. Moreover, administration of large amounts of exogenous VEGF can lead to the formation of leaky 
and haemorrhagic vessels [15]. Thus, exploring new alternatives to the use of exogenous VEGF has critical 
importance. 
Accordingly, we aimed to investigate the angiogenic potential of 2dDR and E2 either applied as solutions 
or released from TE constructs and explore that if it is possible to define certain concentrations of either 
2dDR or E2 which are as effective as VEGF in stimulating angiogenesis in CAM assay.  To date, there have 
been no studies conducted on the effective angiogenic dose range of 2dDR which is proangiogenic. 
Therefore, for the first time in this study, we demonstrated the reliable concentration ranges for both 
2dDR and E2 for stimulating angiogenesis in CAM assay and compared their proangiogenic activities with 
the VEGF used as positive control. 
The key findings from this study were that 2dDR and E2 showed dose-dependent angiogenic responses, 
and our results demonstrate that both were found approximately 80% potent for the production of new 
blood vessels in vivo when compared with VEGF as a positive control which proved to be highly angiogenic 
on the CAM. The results of the dose response studies showed that the most effective doses were 
200ʅg/day/embryo and 200ng/day/embryo for 2dDR and E2, respectively. Higher and lower doses of the 
  
 
drugs showed less angiogenic activity in the CAM assay. These results were further confirmed with the 
investigation of the microvascular structures of CAM when treated with the drugs. In VEGF treated groups, 
the VA% was far higher than in other groups. However, microvessels upregulated by VEGF showed smaller 
lacunae formation due to endothelial cell hypertrophy when assessed with confocal microscopy, while a 
more consistent and stable microvessel structure with a significantly increased VA% was found in 2dDR 
and E2 treated CAMs. This we suggest is important as VEGF has been reported to lead to the formation of 
leaky and haemorrhagic vessels [15].  Although angiogenic activities of 2dDR and E2 were evaluated with 
the direct applications of those to CAM, this administration method is only used for determination of the 
most angiogenic concentrations of the drugs.  
The effective concentrations of 2dDR and E2 were then loaded into electrospun PHBV constructs to 
stimulate angiogenesis with the sustained release of both agents from fibres. PHBV is a natural, 
biocompatible and complete biodegradable biopolymer [55]. Although the biodegradability of PHBV is 
relatively slow when compared with other polymers like PLA and PCL [56,57], it is still an attractive 
material for drug release studies because of  its excellent biocompatibility, biodegradability, easy 
processing properties [58].  
Incorporation of 2dDR and E2 into the PHBV scaffolds resulted in some alterations in fibre morphology 
and hydrophobicity of the scaffolds although no technical problems or adverse effects of introducing E2 
and 2dDR into fibres were experienced. 
Introduction of both drugs significantly increased fibre diameters in accordance with the increasing 
concentrations of the drugs, and there appears to be a change in the fibre structure of electrospun PHBV 
scaffolds that contain higher concentrations of E2. Physical cross-linking of electrospun fibres (or fibre 
fusion) was observed in PHBV scaffolds loaded with the higher dose of E2. The fibre fusion can be 
explained with the decrease in viscosity of the electrospinning solution with the addition of E2, highly 
plasticizing agent [59]. This decrease in viscosity leads to slow evaporation of the solvent during 
electrospinning [60] which results in fused fibres. Unnithan et al. also reported similar changes in fibrous 
morphology of E2 loaded electrospun polyurethane (PU) scaffolds due to change of viscosity of the 
electrospinning solution [61]. On the other hand, the incorporation of 2dDR into the electrospun PHBV 
scaffolds did not affect fibre ultrastructure. However, although the SEM images did not show any change 
in fibre structure, we do observe reduced integrity of the fibres in histologic sections of 2dDR releasing 
scaffolds. These alterations occurred after the scaffolds were implanted on CAM. Therefore, it is likely 
that this change was due to rapid deformation of the fibres after the rapid release of 2dDR resulting in an 
increased surface area for cellular attachment and infiltration. 
Addition of E2 significantly increased the hydrophobicity of the scaffolds in a dose dependent manner. 
This is not surprising as E2 is known to be highly hydrophobic [62]. In contrast to E2, the addition of 2dDR 
significantly decreased the hydrophobic character of the PHBV fibres which can be explained by the high 
solubility of 2dDR in water. The estimated solubility of E2 in water is approximately 30000 times lower 
than sugars [63,64]. Thus, the addition of these drugs with different solubilities significantly changed the 
hydrophilicity of the PHBV scaffolds. Furthermore, this had a reflection on the release characteristics. As 
can be expected, we observed significantly lower and slower release of E2 in comparison with the release 
  
 
of 2dDR from the PHBV fibres. In contrast to the lower and more sustained release of E2 from PHBV fibres, 
a burst release of 2dDR was observed within 7-days.  
Incorporation of both drugs enhanced both UTS and stiffness of the PHBV scaffolds compared with plain 
PHBV controls. The most interesting finding was that scaffolds with highest concentrations of E2 had the 
highest UTS and lowest stiffness. This is more likely to be due to the incorporation of E2 which is acting as 
a plasticizer within the electrospinning solution, changing the viscosity and leading to formation of larger 
diameter and fused fibres which could provide additional rigidity [65]. Huang et al. reported a similar 
change in tensile properties of their drug loaded PCL electrospun scaffolds. They demonstrated that the 
diameters of the fibres were increased with the addition of higher concentrations of the resveratrol (a 
kind of antioxidant), and the addition of the drug led to an increased ultimate strength and decreased 
stiffness of their scaffolds [66]. 
Although both of the factors stimulated angiogenesis when applied directly on CAM, a more dramatic 
increase in the number of discernible blood vessels was seen when 2dDR and E2 releasing PHBV scaffolds 
implanted on CAM. E2 was found to be slightly more effective in both application procedures when 
compared with 2dDR loaded and plain PHBV control groups. This study also established effective 
concentrations of E2 (25mg/g of PHBV) and of 2dDR (250mg/g of PHBV) to be loaded into scaffolds to 
achieve a reliable stimulation of neovascularisation. Higher doses of both drugs were found to be less 
effective in promoting the angiogenesis in CAM assay. The dose dependence of E2 has been studied by 
many groups. In 2004, Seo et al. reported E2 caused an increased angiogenic activity in vivo in a dose 
dependent manner [46]. Pence et al. studied the endogenous VEGF production of epithelial cells when 
treated with different doses of E2 in vitro. They found that the treatment of cells with 10 nM and 1000 
nM E2 stimulated the production of VEGF where addition of 100 nM E2 showed no significant effect on 
cells [47]. Liu et al. examined the effect of E2 on rat cardiac microvascular endothelial cell (CMEC) 
proliferation and tube formation in vitro. With regards to the proliferation of CMECs, they reported a 
biphasic response to E2. The lowest and the highest doses of E2 were less effective compared to the 
optimal dose [48].  In contrast to studies of dosage response of E2, to date there have not been any such 
studies exploring the angiogenic response to different doses of 2dDR. In view of the comparatively few 
studies on this small sugar, not all of which agree, we conducted a dose dependence study of 2dDR for 
promoting angiogenesis. While lower doses of promoted angiogenesis, higher doses were found less 
effective. Drug releasing scaffold assays further confirmed these findings. The scaffolds loaded with the 
higher doses of 2dDR and E2 showed reduced angiogenic activity when compared with the scaffolds 
loaded with lower doses.  
These results were then compared with the histologically stained sections of the scaffolds. In these, more 
blood vessels were counted adjacent to 2dDR and E2 releasing scaffolds. However, in contrast to the 
results from the quantified macro images, in histological analysis, the number of blood vessels adjacent 
to the scaffolds loaded with the higher doses of 2dDR (2dDR 500) and E2 (E2 50) were not significantly 
but slightly greater than lower doses. These differential results might be caused by our ability to see and 
count the smaller diameter blood vessels that may not be discernible in the digital CAM analysis used for 
quantification. Additionally, the histological sections also show blood vessels from different orientations 
  
 
which might not have been detectable on digital CAM images. This might increase the results seen for 
higher doses of the drugs. 
E2 has previously been reported as angiogenic both in vitro and in vivo by many groups as well as our 
research group. Albrecht et al. suggested that E2 promotes angiogenesis through up-regulation of VEGF. 
They reported rapidly increased VEGF expression and cell permeability by E2 administration to 
ovariectomized baboons [67]. Similarly, elevated VEGF mRNA expression levels were observed in 
ovariectomized rats after E2 treatment by Hyder et al. [68]. Morales et al. reported that E2 promoted 
migration of HUVECs and formation of capillary-like networks on matrigel [30]. Pence et at. indicated that 
exogenous E2 promoted endogenous production of VEGF by endometrial epithelial cells [47]. More 
recently our group has demonstrated release of E2 from both biodegradable PLA fibres [36] and from 
nondegradable PU fibres [69] with both electrospun scaffolds showing good proangiogenic activity in the 
CAM assay. 
With respect to 2dDR, we recently published on a hydrogel containing this sugar that showed strong 
proangiogenic activity in the CAM assay and greatly accelerated wound healing in a rat skin model [45]. 
However, when it comes to the mechanism of action and the effective dose range of deoxy sugars, there 
is relatively little literature and it is contradictory. In 2010, Merchan et al. reported anti-angiogenic activity 
of 2-deoxy-D-Glucose (2-DG). They reported that, 2-DG inhibited endothelial capillary formation and 
endothelial cell migration in vitro [70]. In contrast there are a few studies which have reported 2dDR to 
be proangiogenic. Haraguchi et al. examined the angiogenic potential of the degradation products of 
thymidine on CAMs and found 2dDR induced angiogenesis in 72% of their eggs. They also reported its 
chemotactic activity in vitro and angiogenic activity in vivo [43]. Vara et al. recently published a detailed 
study exploring the mechanism of action of 2dDR in regulating angiogenesis. They found 2dDR induces 
angiogenesis by paracrine signalling. The 2dDR directly activates NADPH oxidase 2 (NOX2) which in turn 
triggers nuclear factor Kappa B (NF-ʃ ?ǁŚŝĐŚƵƉƌĞŐƵůĂƚĞƐǀĂƐĐƵůĂƌĞŶĚŽƚŚĞůŝĂůŐƌŽǁƚŚĨĂĐƚŽƌƌĞĐĞƉƚŽƌ ?
(VEGFR2) and vascular endothelial growth factor-dependent angiogenesis [71]. Irrespective of the 
mechanism of action and dose response, our initial results looking at the response to hydrogels releasing 
2dDR were very encouraging. 2dDR loaded chitosan (CS)/collagen hydrogels were firmly attached to the 
wound bed of full thickness excisional wounds (20 mm) in rats by day 3 and wounds treated with 2dDR, 
were completely closed by day 17 with clear hair growth while control wounds remained open with no 
evidence of epithelial tissue or hair growth. The histology of the wound beds of all animals sacrificed at 
day 17 showed complete healing in the case of 2dDR treated wounds with well-developed hair follicles 
and the presence of new blood vessels in the healed wounds was confirmed with CD34 staining [45]. 
In the assessment of these approaches to overcome delayed angiogenesis in tissue engineered constructs 
we have made extensive use of the ex-ovo CAM assay to evaluate angiogenesis. It is an excellent bioassay 
for assessing the angiogenic response to materials allowing direct imaging and comparison of the newly 
formed blood vessels. It can also be used as a low cost, rapid and simple tool for testing very early tissue 
reactions to biomaterials [72]. The CAM assay has been used by our group in recent years to evaluate the 
biocompatibility and proangiogenic response to a range of different polymers encompassing PLA, PU, 
PHBV, and CS/collagen.  
  
 
To place the current results in context we summarise these preceding studies in a table which summarises 
the response of the ex-ovo CAM assay to these materials in terms of their effect on the structure of the 
underlying membrane, the infiltration of cells into the material and their effect on angiogenesis in the 
CAM. Cellular infiltration in the table describes the migration of cells from CAM to biomaterials. In general, 
highly porous, biocompatible structures where pore sizes are large enough to allow cellular ingrowth lead 
to good cellular/tissue infiltration to a biomaterial [73,74]. Because the diameter of the fibres and the 
pore size of electrospun PHBV were much smaller, less cellular infiltration was observed in all PHBV 
scaffold groups than for other polymers studied in the CAM assay (Table 1). 
Table 1. Comparison of response of chorioallantoic membrane to different polymer systems, assessing 
biocompatibility and proangiogenic activity 
 
While the current study makes a novel contribution to the literature on 2dDR by demonstrating a 
significant angiogenic response to different doses of 2dDR and 2dDR loaded PHBV scaffolds, there is much 
needed to be clarified about the angiogenic potential of this small deoxy sugar. We did not attempt to 
study the mechanism of action of 2dDR in promoting angiogenesis in this study. Our focus was to explore 
the dose response of 2dDR for promoting angiogenesis instead. With a biphasic dose-response curve, it 
raises the question of how different doses are acting in the promotion of angiogenesis. Higher or lower 
doses of the drugs can be not effective or even anti-angiogenic. That is why we did achieve our primary 
objective of determining what concentration range of 2dDR is necessary for effective stimulation of 
angiogenesis, and how effective 2dDR is when compared to E2 and VEGF.  That is why we did achieve our 
primary objective of determining what concentration range of 2dDR is necessary for effective stimulation 
of angiogenesis, and how effective this is compared to E2 and VEGF. Although the CAM assay is a really 
useful assay for assessing the initial angiogenic response to biomaterials, the chick embryo does not have 
a fully developed immune system. Therefore, further animal studies will be needed to assess the 
inflammatory response to 2dDR (and E2) releasing PHBV scaffolds. In the current study, our main interest 
was to promote neovascularisation at the site of implantation by delivering drugs that would also 
potentially increase engraftment of TE constructs.  We have now commenced further animal studies with 
2dDR using a model of compromised wound healing. Beyond this, we will explore the engraftment and 
survival of tissue-engineered constructs by adding this sugar or incorporating it into the fibres of scaffolds 
prior to assembly of the tissue engineered construct.  
 
  
 
5. CONCLUSION 
We conclude that both direct application of 2dDR and E2 and the gradual release of these factors from 
PHBV fibres stimulated angiogenesis in an ex-ovo CAM assay. These two small stable factors were readily 
incorporated into electrospun fibres such as those that would be used for tissue-engineered constructs 
and have great potential to be used for functionalisation of the TE scaffolds to promote angiogenesis in 
vivo. Both gave results approximately 80% as effective as the addition of VEGF. In this study, the dose 
dependent angiogenic response to 2dDR has been demonstrated for the first time. 
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SUMMARY POINTS 
Background 
o Delayed neovascularisation following implantation is a major problem for translation of tissue 
engineered (TE) constructs to the clinic.  
o One approach is to combine a TE scaffold with a proangiogenic growth factor such as vascular 
endothelial growth factor (VEGF). VEGF is well-established as a critical factor in promoting 
angiogenesis in vivo but it is labile, expensive and rarely effective unless given at such high 
concentrations. 
o In previous studies, angiogenic potential of E2 has been reported by our group and some 
other groups using different assessment methods. However, although there are many studies 
on dThdPase and assumptions on angiogenic activity of 2dDR as a degradation product by 
dThdPase activity, promoting angiogenesis with 2dDR still needs to be highlighted and 
supported by new studies. 
o The present study was conducted to compare 2dDR, a novel and attractive proangiogenic 
small sugar, and E2, the primary female sex hormone, and to investigate their dose-
dependent effects for the first time in stimulating angiogenesis in comparison with VEGF. 
o This paper aims to form a basis for further understanding of angiogenic potential of 2dDR and 
to encourage scientific groups to explore this small, stable, and angiogenic agent in detail. 
Results 
o The angiogenic potency of 2dDR and E2 was initially assessed in an ex-ovo chick 
chorioallantoic membrane (CAM) assay using different quantification methods in order to 
validate the results. Both were found approximately 80% as potent as VEGF for promoting 
angiogenesis in-vivo. 
o Furthermore, both agents were electrospun into PHBV fibres, and the sustained release of 
both agents from the scaffolds was observed over 30 days. Proangiogenic scaffolds stimulated 
neovascularisation over 7 days in the CAM assay.  
Conclusion 
o The results demonstrated that both direct application of 2dDR and E2 and the gradual release 
of these factors from PHBV fibres stimulated angiogenesis in an ex-ovo CAM assay.  
o These two small stable factors were readily incorporated into electrospun fibres such as those 
that would be used for tissue-engineered constructs and have great potential to be used for 
functionalisation of the TE scaffolds to promote angiogenesis in vivo. 
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